Predictive model for vedolizumab efficacy in moderate-to-severe ulcerative colitis based on computed tomography-derived body compositions and nutritional inflammatory markers

doi:10.4329/wjr.v18.i3.117599

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 3

This Article

(41)

(30)

(0)

(9)

(685)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Radiology

ISSN

1949-8470

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Radiol. Mar 28, 2026; 18(3): 117599
Published online Mar 28, 2026. doi: 10.4329/wjr.v18.i3.117599

Table 1 Baseline clinical characteristics of the study patients, n (%)/mean ± SD

Variables	Total (n = 134)	Test (n = 40)	Train (n = 94)	Statistic	P value
Age	47.84 ± 15.23	45.80 ± 15.94	48.74 ± 14.90	t = -1.03	0.305
BMI	22.15 ± 3.17	21.88 ± 3.19	22.27 ± 3.17	t = -0.66	0.513
SM	119.99 ± 29.89	121.90 ± 30.13	119.14 ± 29.91	t = 0.49	0.624
IMAT	14.45 ± 8.80	14.95 ± 9.70	14.22 ± 8.43	t = 0.44	0.660
SAT	87.21 ± 67.46	88.23 ± 76.85	86.75 ± 63.33	t = 0.12	0.907
VAT	119.90 ± 63.61	121.16 ± 72.38	119.35 ± 59.75	t = 0.15	0.879
Modified Mayo Score	10.13 ± 1.90	9.90 ± 2.08	10.23 ± 1.82	t = -0.91	0.366
HB	115.34 ± 24.48	116.49 ± 19.98	114.83 ± 26.30	t = 0.36	0.719
WBC	7.75 ± 3.50	7.91 ± 3.41	7.69 ± 3.55	t = 0.34	0.736
P	304.04 ± 110.04	301.05 ± 102.56	305.35 ± 113.69	t = -0.21	0.836
ESR	20.62 ± 17.86	15.52 ± 11.81	22.87 ± 19.59	t = -2.23	0.027
CRP	14.76 ± 26.25	8.40 ± 14.15	17.56 ± 29.72	t = -1.88	0.062
ALB	36.75 ± 5.82	38.14 ± 4.94	36.13 ± 6.09	t = 1.85	0.066
N	5.28 ± 2.93	5.41 ± 3.09	5.21 ± 2.87	t = 0.36	0.716
L	1.76 ± 0.85	1.82 ± 0.71	1.73 ± 0.91	t = 0.53	0.598
M	0.50 ± 0.27	0.49 ± 0.21	0.51 ± 0.29	t = -0.46	0.643
Mayo Score	2.84 ± 0.37	2.78 ± 0.42	2.86 ± 0.35	t = -1.15	0.254
Smoking history				χ² = 8.96	0.011
0	108 (80.60)	26 (65.00)	82 (87.20)
1	26 (19.40)	14 (35.00)	12 (12.80)
UC Montreal classification				-	0.657
1	3 (2.24)	1 (2.50)	2 (2.13)
2	29 (21.64)	12 (30.00)	17 (18.08)
3	102 (76.12)	27 (67.50)	75 (79.79)
Clinical response				χ² = 1.87	0.392
0	55 (41.04)	20 (50.00)	35 (37.23)
1	79 (58.96)	20 (50.00)	59 (62.77)
TSpot				χ² = 3.88	0.144
0	120 (89.55)	39 (97.50)	81 (86.17)
1	14 (10.45)	1 (2.50)	13 (13.83)

BMI: Body mass index; SM: Skeletal muscle; IMAT: Intramuscular adipose tissue; SAT: Subcutaneous adipose tissue; VAT: Visceral adipose tissue; HB: Hemoglobin; WBC: White blood cell; ESR: Erythrocyte sedimentation rate; CRP: C-reactive protein; ALB: Albumin; N: Neutrophil; L: Lymphocyte; M: Monocyte; UC: Ulcerative colitis; TSpot: T-Spot.TB.

Full Size Table

Citation: Zhang XY, Li YK, Tian ZB, Guo QY, Liu JN, Liu RQ, Ren KY. Predictive model for vedolizumab efficacy in moderate-to-severe ulcerative colitis based on computed tomography-derived body compositions and nutritional inflammatory markers. World J Radiol 2026; 18(3): 117599
URL: https://www.wjgnet.com/1949-8470/full/v18/i3/117599.htm
DOI: https://dx.doi.org/10.4329/wjr.v18.i3.117599

Zhang XY, Li YK, Tian ZB, Guo QY, Liu JN, Liu RQ, Ren KY. Predictive model for vedolizumab efficacy in moderate-to-severe ulcerative colitis based on computed tomography-derived body compositions and nutritional inflammatory markers. World J Radiol 2026; 18(3): 117599 [PMID: 41937988 DOI: 10.4329/wjr.v18.i3.117599]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.